SPRO Spero Therapeutics, Inc.

Nasdaq sperotherapeutics.com


$ 2.40 $ -0.03 (-1.23 %)    

Thursday, 06-Nov-2025 13:35:35 EST
QQQ $ 614.24 $ -7.55 (-1.21 %)
DIA $ 469.67 $ -2.36 (-0.5 %)
SPY $ 671.93 $ -4.54 (-0.67 %)
TLT $ 89.67 $ 0.11 (0.12 %)
GLD $ 366.96 $ -0.24 (-0.07 %)
$ 2.43
$ 2.43
$ 2.39 x 943
$ 2.40 x 4,611
$ 2.38 - $ 2.44
$ 0.51 - $ 3.22
596,286
na
136.75M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-11-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
24 11-04-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-14-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 04-02-2018 12-31-2017 10-K
32 12-14-2017 09-30-2017 10-Q
33 11-05-2015 09-30-2015 10-Q
34 08-06-2015 06-30-2015 10-Q
35 05-05-2015 03-31-2015 10-Q
36 03-24-2015 12-31-2014 10-K
37 11-04-2014 09-30-2014 10-Q
38 08-07-2014 06-30-2014 10-Q
39 05-06-2014 03-31-2014 10-Q
40 03-25-2014 12-31-2013 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral...

 spero-therapeutics-q2-eps-003-beats-038-estimate-sales-14189m-up-from-10197m-yoy

Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(...

 benzinga-bulls-and-bears-nvidia-palantir-marvell-technology--and-markets-rallied-in-may

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...

 why-is-gsk-partner-spero-therapeutics-stock-skyrocketing-on-wednesday

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapen...

Core News & Articles
Market-Moving News for May 28th
05/28/2025 11:16:13

OKTA: -13% | Okta shares are trading lower following the company's Q1 earnings report. In its outlook, the company said it ...

 spero-therapeutics-q1-eps-025-beats-055-estimate-sales-587m-miss-1100m-estimate

Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION